Therapy

Pefloxacin Shows Promise in Combination TB Treatment

Published in TB and Outbreaks Week, July 10th, 1995

The fluoroquinolone pefloxacin may have a role in combination therapy for the retreatment of pulmonary tuberculosis, according to a report from India.

Pretreatment resistance to rifampin is not common in most countries, but it may become more prevalent due to the increasing use of rifampin-containing regimens for the treatment of tuberculosis.

The incidence of acquired resistance to rifampin was reported to have increased from 2.8 percent in 1983 to 37.3 percent in 1986. Additional treatment of such patients is usually difficult because available drugs are usually expensive, toxic, and sometimes not effective.

"Recent reports...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1995-07-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry